Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes

Journal of Clinical Pharmacology

Volumn 51, Issue 2, 2011, Pages 173-180

  Loebstein, Ronen ^a,b   Dushinat, Marina ^a   Vesterman Landes, Janet ^a   Silverman, Barbara ^a   Friedman, Nurit ^a   Katzir, Itzhak ^a   Kurnik, Daniel ^a   Lomnicky, Yossef ^a   Kokia, Ehud ^a,b   Halkin, Hillel ^a,b  

^a MACCABI HEALTHCARE SERVICES   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

acute coronary syndrome; acute myocardial infarction; Rosiglitazone

Indexed keywords

METFORMIN; ROSIGLITAZONE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; DATA BASE; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; HAZARD RATIO; HEART MUSCLE REVASCULARIZATION; HUMAN; LONG TERM CARE; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; UNIVARIATE ANALYSIS;

AGED; CARDIOVASCULAR DISEASES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES; THIAZOLIDINEDIONES;

EID: 79551718145     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010368281     Document Type: Article

References (33)

1. Richter B., Bandeira-Echtler E., Bergerhoff K., Clar C., Ebrahim S. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007 ;(3). CD006063.
2. Wagstaff AJ, Goa KL Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2002 ; 62: 1805-1837.
3. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care. 2002 ; 25 (suppl 1). S74 - S77.
4. Zinman B. PPAR? agonists in type 2 diabetes: how far have we come in preventing the inevitable? A review of the metabolic effects of rosiglitazone. Diabetes Obes Metab. 2001 ; 3 (suppl 1). S34 - S43.
5. Campbell IW The clinical significance of PPAR gamma agonism. Curr Mol Med. 2005 ; 5: 349-363.
6. Cheng PT, Mukherjee R. PPARs as targets for metabolic and cardiovascular diseases. Mini Rev Med Chem. 2005 ; 5: 741-759.
7. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007 ; 356: 2457-2471.
8. Singh S., Loke YK, Furberg CD Long-term risk of cardiovascular events with rosiglitazone: a meta analysis. JAMA. 2007 ; 298: 1189-1195.
9. Lago RM, Singh PP, Nesto RW Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomized clinical trials. Lancet. 2007 ; 370: 1129-1136.
10. Selvin E., Bolen S., Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications. Arch Intern Med. 2008 ; 168: 2070-2080.
11. Murlow CD, Cornell JE, Localio AR Rosiglitazone: a thunder-storm from scarce and fragile data. Ann Intern Med. 2007 ; 147: 585-587.
12. Diamond GA, Bax L., Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med. 2007 ; 147: 578-581.
13. Home PD, Pocock SJ, Henning BN, et al. Rosiglitazone evaluated for cardiovascular outcomes: an interim analysis. N Engl J Med. 2007 ; 357: 28-38.
14. Home PD, Pocock SJ, Beck-Nielsen H., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomized, open-label trial. Lancet. 2009 ; 373: 2125-2135.
15. Koro CE, Fu Q., Stender M. An assessment of the effect of thazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients. Pharmacoepidemiol Drug Saf. 2008 ; 17: 989-996.
16. Walker AM, Koro CE, Landon J. Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007. Pharmacoepidemiol Drug Saf. 2008 ; 17: 760-768.
17. Clifford J., Rosen MD The rosiglitazone story: lessons from an FDA advisory committee meeting. N Engl J Med. 2007 ; 357: 844-846.
18. Margolis DJ, Hoffstad O., Storm BL Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf. 2008 ; 17: 753-759.
19. Lipscombe LL, Gomes T., Levesque LE, Hux JE, Juurlink D., Alter DA Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 2007 ; 298: 2634-2643.
20. Wolfgang C., Winkelmayer WC, Setoguchi S., Levin R., Solomon DH Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med. 2008 ; 168: 2368-2375.
21. Rosiglitazone no longer recommended. Lancet. 2008 ; 372: 150.
22. Shalev V., Chodick G., Bialik M., Green MS, Heymann AD In a population-based cohort of diabetes patients, men and women had similar risks for all cause mortality. J Clin Epidemiol. 2007 ; 60: 86-93.
23. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2007 ; 30: S42 - S47.
24. Steiner JF, Prochazka AV The assessment of refill compliance using pharmacy records: methods, validity and applications. J Clin Epidemiol. 1997 ; 50: 105-116.
25. Psaty BM, Furberg CD The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med. 2007 ; 357: 67.
26. Rucker G., Schumacher M. Simpson's paradox visualized: the example of the rosiglitazone meta-analysis. BMC Med Res Methodol. 2008 ; 8: 34.
27. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 ; 329: 977-986.
28. Stettler C., Allemann S., Juni P., et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J. 2006 ; 152: 27-38.
29. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998 ; 352: 837-853.
30. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 ; 358: 2560-2572.
31. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 ; 358: 2545-2559.
32. Duckworth W., Abraira C., Moritz T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. The VADT study. N Engl J Med. 2009 ; 360: 129-139.
33. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 ; 359: 1577-1589.